Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Congress backs CDRH raise

This article was originally published in The Gray Sheet

Executive Summary

Senate votes 93-1 to spend $209.3 mil. for device center in FY 2004 agriculture approps bill Nov. 6, including $29.2 mil. in user fees. The House-cleared report offers $193.5 mil. in CDRH budget authority, while the Senate report originally proposed $191.9 mil. (1"The Gray Sheet" Nov. 3, 2003, p. 5). In its request to reconcile the amounts, the Senate appointed 17 conferees...

You may also be interested in...



Omnibus appropriations

Senate may reconvene in December to consider seven-bill spending package, which would dole out $209.4 mil. for CDRH in agriculture appropriations conference report provision. The House is scheduled to consider the legislation when it reconvenes during the week of Dec. 8; Senate options include funding FDA at FY 2003 levels under a continuing resolution through Jan. 31, 2004, or unanimous consent passage before year-end. The amount closely aligns with the Senate bill, passed Nov. 6 (1"The Gray Sheet" Nov. 10, 2003, In Brief)...

OMB’s FY 2005 Device Funding Request Leaves Industry Wary Of FDA Estimate

Legislative changes to the compensating adjustment factor affecting device user fee rates in fiscal 2005 and beyond could be accomplished if Congress revisits the MDUFMA "triggers" in 2004

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019286

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel